OPTIX
Price
$115.43
Change
+$1.19 (+1.04%)
Updated
Jun 2 closing price
Net Assets
6.37B
RGACX
Price
$85.14
Change
-$0.28 (-0.33%)
Updated
Jun 2 closing price
Net Assets
337.53B
Interact to see
Advertisement

OPTIX vs RGACX

Header iconOPTIX vs RGACX Comparison
Open Charts OPTIX vs RGACXBanner chart's image
OPTIX vs RGACX Comparison Chart in %
View a ticker or compare two or three
VS
OPTIX vs. RGACX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OPTIX is a Hold and RGACX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGACX has more cash in the bank: 338B vs. OPTIX (6.37B). OPTIX (0.00) and RGACX (0.00) have matching dividends . OPTIX was incepted earlier than RGACX: OPTIX (14 years) vs RGACX (24 years). RGACX (0.93) is less costly to investors than OPTIX (0.63). OPTIX is a more actively managed with annual turnover of: 63.00 vs. RGACX (32.00). RGACX has a lower initial minimum investment than OPTIX: RGACX (250) vs OPTIX (1000000). OPTIX (14.48) and RGACX (14.24) have marching annual gain over last year. OPTIX return over 5 years is better than : 29.60 vs. RGACX (22.53).
OPTIXRGACXOPTIX / RGACX
Total Expense Ratio0.630.9368%
Annual Report Gross Expense Ratio0.630.9368%
Fund Existence14 years24 years-
Gain YTD10.20610.29199%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets6.37B338B2%
Annual Yield % from dividends0.000.00-
Returns for 1 year14.4814.24102%
Returns for 3 years69.9551.07137%
Returns for 5 years29.6022.53131%
Returns for 10 years109.84107.79102%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OVLY33.800.92
+2.80%
Oak Valley Bancorp (CA)
PDD88.180.94
+1.08%
PDD Holdings
URBN72.260.74
+1.03%
Urban Outfitters
BAFN5.82-0.09
-1.52%
BayFirst Financial Corp
BCAX19.63-0.99
-4.80%
Bicara Therapeutics Inc.